Eli Lilly Chief Executive Officer Dave Ricks talks about paying $2.5 billion for a cancer drug being developed by Scorpion Therapeutics. He also says Lilly's experimental weight-loss pill could be approved in early 2026. He speaks to Bloomberg's Katie Greifeld from the JPMorgan Healthcare Conference in San Francisco.

Charles Schwab Chief Fixed Income Strategist Kathy Jones Talks Treasuries and Fed Interest Rates
07:39

President and CEO of Stew Leonard's, Steward Leonard Jr., Talks Consumer Spending and War Impact
06:06

Democratic Senator Gary Peters of Michigan Talks Pentagon Funding, Rising Gas Prices
11:20